Incidence and Impact of Ventilator Associated Multidrug Resistant Pneumonia in Patients with SARS-COV2
Table 1
Demographic and comorbidity distributions.
Total
VAP
No VAP
N
148
41
107
Age, mean (years)
60
58.6
60.5
0.5
Sex, %
Male, n (%)
86 (58)
26 (63)
60 (56)
0.4
Female, n (%)
62 (42)
15 (37)
47 (44)
0.4
Race, %
Black
99 (70)
24 (62)
75 (74)
0.2
White
10 (7)
4 (10)
6 (6)
0.4
Native American
1 (1)
0 (0)
1 (1)
—
Other
31 (21)
11 (28)
20 (20)
0.3
Ethnicity, %
Hispanic
30 (20)
12 (32)
18 (19)
0.09
Nonhispanic
102 (69)
26 (68)
76 (81)
0.4
Comorbidities, %
Cancer
29 (20)
4 (10)
25 (23)
0.03
Diabetes mellitus
86 (58)
27 (66)
59 (55)
0.2
Heart disease
95 (64)
29 (71)
66 (62)
0.3
Hypertension
99 (67)
25 (61)
74 (69)
0.5
Immune disorder
18 (12)
4 (10)
14 (13)
0.6
Chronic kidney disease
23 (16)
9 (22)
14 (13)
0.2
Chronic liver disease
24 (16)
9 (22)
15 (14)
0.2
Prior CVA
7 (5)
3 (7)
4 (3)
0.7
BMI, mean
32.9
34.2
32.4
0.3
Highest SOFA score within 48 hours of admission (mean)
6
6
5
0.4
Highest SOFA score prior to ICU admission (mean)
13
14
13
0.03
Empiric antibiotic prior to IMV (%)
60 (41)
24 (59)
60 (56)
0.8
Empiric antibiotic within 48 hours of IMV (%)
120 (81)
36 (88)
84 (79)
0.2
Discharge disposition, n (%)
Mortality
81 (55)
20, (49)
61, (57)
0.4
Home
40 (27)
6, (15)
34, (32)
0.04
Skilled facility
28 (19)
15, (37)
13, (12)
<0.001
ICU LOS, mean (d)
20
30
16
<0.001
Hospital LOS, mean (d)
22
35
17
<0.001
values by chi-squared or welch’s t-test. value calculated by chi-squared; value calculated by welch’s t-test P values by t-test for VAP by each variable. VAP–ventilator associated pneumonia; CVA–cerebrovascular accident; BMI–body mass index; SOFA–sequential organ failure assessment; IMV–invasive mechanical ventilation; ICU–intensive care unit; LOS–length of stay.
